Calls for papers
-
Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company’s new scientific advisory board. Joining Cunningham on Prosonix’s SAB are: Peter Barnes, Professor of Thoracic Medicine… Read more . . .
-
Massachusetts respiratory pharmaceutical company Acton Pharmaceuticals has entered into a licensing agreement with Sanofi US that gives Acton exclusive US rights to develop and market prescription Nasacort HFA triamcinolone acetonide nasal aerosol for the treatment… Read more . . .
-
Merck has announced results of two Phase 3 clinical studies of Dulera mometasone furoate/formoterol fumarate inhalation aerosol for the treatment of COPD that show statistically significant improvement in lung function in most of the combinations… Read more . . .
-
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Pharmaxis has adopted a positive opinion recommending the approval of a marketing authorization for Bronchitol inhaled dry powder mannitol formulation “for the treatment… Read more . . .
-
Over the past few months, the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ) has issued several statistical briefs and a research finding regarding rising expenditures for asthma medications used… Read more . . .
-
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of… Read more . . .
-
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other’s technologies. The partnership also gives Bend… Read more . . .
-
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092… Read more . . .
-
Hovione has launched a new service to provide proof of concept formulation for new dry powder formulations within a few weeks. The company says that its Rapid Proof of Concept Study will further simplify DPI… Read more . . .
-
SkyePharma has announced a delay in the review of the European Marketing Authorisation Application (“MAA”) for the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) because the 21 Concerned Member States failed to reach consensus… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden